The information is based on current knowledge of COVID-19 and will be updated as more scientific evidence is released.

Potential treatment options

1. Hydroxychloroquine

Hydroxychloroquine is used against SARS-CoV-2 in two folds: it decreases viral replication through T-cell suppression and it inhibits the immune response (cytokine storm) caused by the viral infection.
There is some evidence to suggest taking Azithromycin on top of Hydroxychloroquine may be effective against severe bacterial respiratory infections that arise from SARS-CoV-2, but take this information with caution because the study was not well powered.
Note that current dosing is based on previous clinical experience, and adverse effects may occur. Current clinical trials are underway.

Source:

2. Remdesivir

Remdesivir is an investigational drug that interferes with virus replication by inhibiting viral RNA polymerase; it has shown to be effective against SARS (severe acute respiratory syndrome) and MERS (middle eastern respiratory syndrome) in the past.
Preclinical data suggests that it may have potent activity against SARS-CoV-2, although human data regarding efficacy and safety is limited.
Remdesivir can be obtained for hospitalized patients with COVID-19 in the United States through clinical trials and Gilead's expanded access program (available soon).

3. Lopinavir/Ritonavir (Kaletra)

Kaletra is a retroantiviral medication that has reduced viral loads and risk of adverse events in patients with SARS and MERS.
One randomized controlled trial involving patients in Wuhan found that Kaletra did not decrease viral load, improve clinical improvement, or reduce mortality.

4. Tocilizumab (Actemra)

Tocilizumab is an immunosuppressive drug that may be helpful against COVID-19 patients with cytokine storm, which is an elevated immune response to foreign particles, such as the SARS-CoV-2 virus.
According to the current Novel Coronavirus Pneumonia Diagnosis and Treatment Plan, Tocilizumab is recommended for patients with elevated biomarkers for immune response as well as extensive/bilateral lung disease.
Note that because secondary bacterial infections are common in patients with COVID-19, patients on Tocilizumab will need to be monitored carefully.
Tocilizumab is currently undergoing phase III clinical trials in the US and is being used in China for COVID-19 patients

5. Zinc

Zinc is a potent inhibitor of RNA viruses in vitro, such as the SARS-CoV-2, by interfering with viral protein processing; this means that virus parts will have a harder time assembling into mature viruses.
Zinc-ionophores such as Hydroxychloroquine will increase the absorption of Zinc into the body and may lead to cardiovascular side effects due to a higher level of positive ions in the body.

6. Ivermectin

Ivermectin inhibits the replication of SARS-CoV-2 in vitro, in theory, by inhibiting the transport of viral proteins
Ivermectin is a FDA approved medication used against parasites, but was found to have broad range antiviral activity.

7. Convalescent Plasma

Convalescent plasma uses antibodies from those recovered to treat COVID-19 patients, which has seen success in the past in SARS, MERS, and H1N1 epidemics
Investigators will be studying the use of convalescent plasma in clinical trials soon